publication date: Mar. 16, 2018
Issue 11 - Mar. 16, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Do patients know best? Industry, NCI committing dollars to studying patient-reported outcomes

    Researchers are coming to the conclusion that cancer patients are the best authority on how therapies affect them.

    Over the past few years, about 20 NCI trials and over 125 industry studies have incorporated direct reports of symptomatic adverse events by cancer patients through an NCI program.

  • Conversation with the Cancer Letter

    Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable

    Fifteen years ago, when Ethan Basch started developing measures for aggregating patient-reported outcomes, many of his colleagues in oncology saw no promise in this enterprise.

  • Conversation with the Cancer Letter

    Porter: I can’t tell you how the Trump administration gets its budget numbers

    John Edward Porter, a long-time key Congressional appropriator and advocate for biomedical research, received the Research!America Legacy Award at an advocacy awards dinner March 14.

  • In Brief

    • President’s Cancer Panel calls for urgent action on drug prices
    • AACR launches initiative focused on health disparities in African-Americans
    • Aurora Health Care & UTHealth join  Strata Oncology
    • PRIMO Lara named deputy chair of SWOG
    • Fox Chase’s Engstrom receives lifetime achievement award for cancer prevention
    • Bellerjeau gets lifetime achievement award from blood and marrow transplant group
  • TCCL Logo

  • Trials and Tribulations

    Rare Cancers, Common Need

    Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

  • Clinical Roundup

    • ASTRO issues updated clinical guideline for whole breast radiation therapy
    • Testicular cancer survivors need screening for long-term heart disease risk
  • Drugs and Targets

    • Erdafitinib gets Breakthrough Therapy designation for metastatic urothelial cancer
    • FDA grants priority review to Merck’s sBLA for Keytruda for advanced cervical cancer

Copyright (c) 2018 The Cancer Letter Inc.